JANX — Janux Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1817713 ·
Last close
$16.40
Market Cap
$1.00B
52W High
$16.91
52W Low
$12.98
ADV30
1,248,921
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,733,000 | — | -34,213,000 | -24,361,000 | 1,028,225,000 | 51,828,000 | 86,690,000 |
| Dec 2025 | 0 | — | -42,401,000 | -31,946,000 | 1,001,565,000 | 52,334,000 | 44,743,000 |
| Sep 2025 | 10,000,000 | — | -35,251,000 | -24,313,000 | 1,024,766,000 | 48,389,000 | 48,211,000 |
| Jun 2025 | 0 | — | -45,118,000 | -33,858,000 | 1,032,212,000 | 52,446,000 | 41,696,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,235,000
Investing CF
$-300,981,000
Financing CF
$4,945,000
CapEx
$-1,043,000
Dividends Paid
—
Buybacks
$-347,000
EPS Diluted TTM
$-1.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-351,382,000
Inventory
—
Receivables
$6,428,000
ST Investments
$914,233,000
EBIT TTM
$-157,667,000
Pretax Income TTM
$-113,625,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,733,000
EBITDA
$-155,004,000
Free Cash Flow
$-54,010,376
Enterprise Value
$86,672,928
Total Cash
$956,385,984
Total Debt
$21,571,000
Shares Out
60,984,354
Trailing EPS
$-1.84
Book Value
$15.47
ROE
-11.7%
ROA
-9.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -157,667,000 | -113,625,000 | 1,001,565,000 | 44,743,000 | — | -82,235,000 |
| Dec 2024 | 10,588,000 | -98,847,000 | -68,994,000 | 1,061,516,000 | 38,735,000 | — | -43,814,000 |
| Dec 2023 | 8,083,000 | -72,979,000 | -58,293,000 | 380,407,000 | 36,058,000 | — | -50,575,000 |
| Dec 2022 | 8,612,000 | -67,091,000 | -63,059,000 | 364,010,000 | 43,270,000 | — | -42,922,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | $1.00B | $25.48 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.00B | $36.61 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $1.01B | $12.61 | — |
| AVTX | Avalo Therapeutics, Inc. | $1.01B | $19.21 | — |
| EVO | Evotec SE | $989.20M | $2.79 | — |
News headlines (Yahoo Finance, 1h cache)
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?
2026-07-09 09:10 · Yahoo
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
2026-07-02 22:40 · Yahoo
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
2026-06-30 13:06 · Yahoo
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
2026-05-28 22:33 · Yahoo
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
2026-05-28 16:53 · Yahoo
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
2026-05-28 13:55 · Yahoo
Here's Why You Should Add JANX Stock to Your Portfolio Now
2026-05-26 15:28 · Yahoo
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
2026-05-23 20:48 · Yahoo
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
2026-05-23 20:37 · Yahoo
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.